WATERTOWN, Mass. - Kymera Therapeutics Inc. (NASDAQ: KYMR), a biopharmaceutical firm focused on advancing protein degradation therapies, has presented promising early clinical data from its Phase 1 trial of KT-333, a novel cancer treatment candidate.
The data, shared at the European Hematology Association Annual Meeting in Madrid, Spain, indicates that KT-333 has shown antitumor activity in several hematological malignancies, including complete responses in two patients with Hodgkin’s lymphoma.
The ongoing trial assesses the safety, tolerability, and efficacy of KT-333 in adults with relapsed or refractory lymphomas, leukemias, and solid tumors. As of June 3, 2024, 47 patients across seven dose levels have been enrolled, receiving an average of 9.1 doses.
Promising outcomes include complete responses in two out of three patients with classic Hodgkin’s lymphoma at one of the dose levels tested. These patients, previously treated with checkpoint inhibitors and brentuximab vedotin, have now undergone potentially curative stem cell transplants.
In addition to Hodgkin’s lymphoma, a patient with NK-cell lymphoma harboring a STAT3 mutation achieved a complete response. Partial responses were observed in four of nine patients with cutaneous T-cell lymphoma, and stable disease was noted in various solid tumor cases.
KT-333, which aims to degrade the STAT3 protein—a key driver of tumor progression and immune response suppression—has demonstrated up to 95% degradation of STAT3 in blood samples and has shown favorable immunomodulatory responses that may complement anti-PD-1 therapies in solid tumors.
The treatment has been well-tolerated, with most adverse events being Grade 1 or 2 in severity, including stomatitis and fatigue. Some dose-limiting toxicities were observed, which will inform the ongoing dose escalation study.
Kymera Therapeutics anticipates completing the Phase 1 trial and sharing a full data set in the second half of 2024, which could provide further insights into KT-333’s potential as a cancer therapy. The company, which specializes in targeted protein degradation, aims to address diseases with unmet medical needs through this emerging therapeutic approach.
This report is based on a press release statement from Kymera Therapeutics.
In other recent news, Kymera Therapeutics has been the recipient of varying analyst ratings and price targets. Piper Sandler has maintained an Overweight rating on the biotechnology firm, keeping a steady price target of $56.00. The firm has highlighted Kymera's recent presentation of new data and progress in drug development programs.
On the other hand, BofA Securities has reduced its price target for Kymera to $43 from $45, while maintaining a neutral stance on the stock, following Kymera's first-quarter results. Oppenheimer, too, has lowered its price target to $52 from $53 but maintains an Outperform rating on the company.
Kymera Therapeutics has been actively progressing in its drug development programs, with significant updates on its drug candidates, KT-621 and KT-294. The company is set to initiate Phase I clinical trials for both drugs in 2024 and 2025 respectively. Furthermore, Kymera, in collaboration with Sanofi (EPA:SASY) (NASDAQ:SNY), is advancing Phase II studies with SAR444656, also known as KT-474, with top-line results expected in 2025.
The company concluded the first quarter of 2024 with a robust cash balance of $745 million, which is projected to fund its operations into the first half of 2027.
InvestingPro Insights
Kymera Therapeutics Inc. (NASDAQ: KYMR) has shown promise with its innovative cancer treatment candidate, KT-333, as it progresses through early clinical trials. The robust clinical outcomes are a beacon of hope for patients, and the financial health of the company is an important factor for investors monitoring Kymera's ability to sustain and advance its research and development efforts.
InvestingPro data reveals a market capitalization of $2.14 billion for Kymera, reflecting investor confidence in the company's potential. Despite not being profitable over the last twelve months, Kymera's revenue has grown significantly by 70.16% as of Q1 2024, indicating a strong upward trajectory in its financial performance. However, it's crucial to note that the company's gross profit margin stands at -146.4%, underscoring the challenges it faces in converting revenues into actual profit.
One of the key InvestingPro Tips for Kymera is that analysts have revised their earnings upwards for the upcoming period, suggesting that the market expects the company's financial situation to improve. This could be indicative of the optimism surrounding KT-333's clinical progress and its potential impact on Kymera's future revenue streams.
Another aspect to consider is that Kymera holds more cash than debt on its balance sheet, which is a positive sign of financial stability. This positions the company well to fund ongoing research and potential commercialization efforts for KT-333 without the immediate need for external financing.
For investors interested in a deeper dive into Kymera's financial health and future prospects, there are additional InvestingPro Tips available at https://www.investing.com/pro/KYMR. These tips can provide valuable insights into the company's valuation, profitability, and market position. To access these insights, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. With 10 more tips listed on InvestingPro, investors can gain a comprehensive understanding of Kymera's investment potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.